Floatz logo

[177lu]lu-sn201

Unresectable Solid Tumor

Spago Nanomedical ABradiopharmaceuticalPhase 1/2Active
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
89/ 100

Competitive context

20 Active assets in the Unresectable Solid Tumor cohort.

Asset / SponsorPhaseRating
Mdna11
Medicenna Therapeutics, Inc.
Phase 1/2CC
Pembrolizumab
Medicenna Therapeutics, Inc.
Phase 1/2CC
Fmc-376
Frontier Medicines Corporation
Phase 1/2CC
LEUPROLIDE
Relay Therapeutics, Inc.
Phase 1CC
Abemaciclib
Relay Therapeutics, Inc.
Phase 1CC

View all 20 →

Same molecule, other indications

[177lu]lu-sn201 is also rated in:

cancerDormant
CCC
Indicative ·
48 / 100
View asset →
Locally Advanced Solid TumorDormant
CC
Indicative ·
45 / 100
View asset →
metastatic malignant neoplasmDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →